GlassScriptPhysician profile
Reed Gibb
NPI 1568569721
$2,682.11
in general payments reported to CMS, 2019-2025
26 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $114 · 2021: $225 · 2022: $515 · 2023: $731 · 2024: $441 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577 · Entertainment: $39.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.45 |
| Entertainment | $39.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $523.72 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $292.58 | 2022-2025 | |
| Genentech USA, INC. | $278.68 | 2022-2025 | Vabysmo, Susvimo |
| Allergan, INC. | $166.25 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $149.59 | 2023-2025 | Syfovre |
| Rxsight INC | $133.72 | 2022-2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Astellas Pharma US INC | $132.08 | 2023-2025 | Izervay |
| Johnson & Johnson Vision Care, INC. | $130.16 | 2022-2025 | Acuvue |
| Amgen INC. | $116.34 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $91.69 | 2019-2022 | |
| Sight Sciences, INC. | $90.18 | 2021 | |
| Bausch & Lomb Americas INC. | $89.50 | 2022-2024 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.18 | 2019-2021 | |
| Alcon Vision LLC | $51.07 | 2022-2025 | Precision7 |
| Horizon Therapeutics Plc | $47.87 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $39.89 | 2019-2021 | |
| Eyepoint US, INC. | $39.62 | 2020-2021 | |
| Optos, INC. | $39.03 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $32.55 | 2024 | Oxervate |
| Biotissue Holdings INC. | $31.22 | 2023-2024 | |
| Oyster Point Pharma, INC. | $23.83 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $23.45 | 2019 | |
| Harrow Eye, LLC | $21.17 | 2025 | Iheezo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech, INC. | $17.75 | 2023 | Vabysmo |
| Coherus Oncology, INC. | $17.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Gibb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.